{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:17:50Z","timestamp":1788016670141,"version":"build-2784847793"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease that is emerging and spreading worldwide. This condition manifests as a hepatic component of the metabolic syndrome, and its occurrence is closely associated with risk factors such as insulin resistance and abdominal obesity. This study aims to review and analyze the cost-effectiveness of diagnostic and screening methods for NAFLD through a systematic review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Searches were conducted in Web of science, Scopus, Pubmed, Embase, National Health Services Economic Evaluation Database, Cochrane Database of Systematic Reviews; DAHTA-Database. NHS Health Technology assessment (Centre for review and. DISSEMMINATION Library-CRD), Cost Effectiveness Analysis Registry. The search covered articles published between January 1990 and December 2023. Studies that were written in English and Persian and examined the cost-utility and cost-effectiveness of diagnosis and screening methods in NAFLD were included in our review. Data extraction was guided by the Consolidated Health Economic Evaluation Reporting Standards checklist, and the quality of economic evaluations was assessed using the Criteria for Health Economic Quality Evaluation tool. All costs were converted to 2024 U.S. dollars using Purchasing Power Parity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The search yielded 1649 studies, and 11 studies were eligible for inclusion. The studies were mainly based on a European setting and then Asian and American alike. Most of the studies used different decision analysis models such as decision tree and Markov to evaluate the cost-effectiveness. The lowest and highest numerical values of outcome measures were 0.021 and 14.46 quality-adjusted life years, respectively. Furthermore, the lowest and highest numerical value of the cost of diagnosis and screening methods in NAFLD were $101, and $123,706, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Policymakers, decision-makers, and healthcare professionals should consider not only the acceptability, accuracy, sensitivity, accessibility, and feasibility of NAFLD screening and diagnostic strategies but also their cost-effectiveness and affordability, taking into account the financial burden of the disease and local and national cost-effectiveness data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijpvm.ijpvm_369_24","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:00:15Z","timestamp":1788015615000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Cost Effectiveness of Diagnosis and Screening Methods in Nonalcoholic Fatty Liver Disease: A Systematic Review"],"prefix":"10.4103","volume":"17","author":[{"given":"Ali Sarabi","family":"Asiyabar","sequence":"first","affiliation":[{"name":"Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin Abolhasanbeigi","family":"Gallehzan","sequence":"additional","affiliation":[{"name":"Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood","family":"Zamandi","sequence":"additional","affiliation":[{"name":"Department of Public Health, School of Health, Sabzevar University of Medical Sciences, Sabzevar, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Rezapour","sequence":"additional","affiliation":[{"name":"Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aghdas","family":"Souresrafil","sequence":"additional","affiliation":[{"name":"Department of Health Services and Health Promotion, Occupational Environment Research Center, School of Health, Rafsanjan University of Medical Sciences, Rafsanjan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marziye","family":"Hadian","sequence":"additional","affiliation":[{"name":"Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaheh","family":"Mazaheri","sequence":"additional","affiliation":[{"name":"Health Information Technology Research Center, Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Khosravi","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Diseases Research Center, Qom University of Medical Sciences, Qom, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7]]},"reference":[{"key":"R1-20260829","doi-asserted-by":"crossref","first-page":"e6585","DOI":"10.1097\/MD.0000000000006585","article-title":"Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients","volume":"96","author":"Phisalprapa","year":"2017","journal-title":"Medicine"},{"key":"R2-20260829","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jhep.2004.09.012","article-title":"The histological course of nonalcoholic fatty liver disease: A longitudinal study of 103 patients with sequential liver biopsies","volume":"42","author":"Adams","year":"2005","journal-title":"J Hepatol"},{"key":"R3-20260829","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/gut.2009.205088","article-title":"Disease progression of non-alcoholic fatty liver disease: A prospective study with paired liver biopsies at 3 years","volume":"59","author":"Wong","year":"2010","journal-title":"Gut"},{"key":"R4-20260829","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/13696998.2022.2026702","article-title":"Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease","volume":"25","author":"Rustgi","year":"2022","journal-title":"J Med Econ"},{"key":"R5-20260829","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"R6-20260829","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"Marchesini","year":"2016","journal-title":"J Hepatol"},{"issue":"Supp l","key":"R7-20260829","first-page":"S103","article-title":"Screening strategy for non-alcoholic fatty liver disease","volume":"29","author":"Zhang","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"R8-20260829","doi-asserted-by":"crossref","first-page":"686","DOI":"10.47102\/annals-acadmedsg.2022284","article-title":"Non-alcoholic fatty liver disease screening in type 2 diabetes mellitus: A cost-effectiveness and price threshold analysis","volume":"51","author":"Choo","year":"2022","journal-title":"Ann Acad Med Singap"},{"issue":"(Supp l)","key":"R9-20260829","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"R10-20260829","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"R11-20260829","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/hep.30094","article-title":"Healthcare cost and utilization in nonalcoholic fatty liver disease: Real-world data from a large US claims database","volume":"68","author":"Allen","year":"2018","journal-title":"Hepatology"},{"key":"R12-20260829","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R13-20260829","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"R14-20260829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2007.02.009","article-title":"Epidemiology and natural history of NAFLD and NASH","volume":"11","author":"Ong","year":"2007","journal-title":"Clin Liver Dis"},{"issue":"(S1)","key":"R15-20260829","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1665-2681(19)31827-7","article-title":"Treatment regimens for non-alcoholic fatty liver disease","volume":"8","author":"Lam","year":"2009","journal-title":"Ann Hepatol"},{"key":"R16-20260829","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/postgradmedj-2018-136316","article-title":"Diagnosis and management of non-alcoholic fatty liver disease","volume":"95","author":"Jennison","year":"2019","journal-title":"Postgrad Med J"},{"key":"R17-20260829","doi-asserted-by":"crossref","first-page":"108","DOI":"10.33590\/emj\/10314271","article-title":"Practical diagnosis and staging of nonalcoholic fatty liver disease: A narrative review","volume":"3","author":"Gallacher","year":"2018","journal-title":"EMJ"},{"key":"R18-20260829","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.24452","article-title":"Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis","volume":"54","author":"Hernaez","year":"2011","journal-title":"Hepatology"},{"key":"R19-20260829","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.metabol.2017.04.003","article-title":"Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic\/histological parameters in various liver diseases","volume":"72","author":"Ballestri","year":"2017","journal-title":"Metabolism"},{"key":"R20-20260829","doi-asserted-by":"crossref","first-page":"106175","DOI":"10.1016\/j.cct.2020.106175","article-title":"The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease","volume":"98","author":"Hardy","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"R21-20260829","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.aohep.2020.09.006","article-title":"Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease","volume":"19","author":"Arab","year":"2020","journal-title":"Ann Hepatol"},{"key":"R22-20260829","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/jgh.13857","article-title":"Asia\u2013Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017\u2014part 1: Definition, risk factors and assessment","volume":"33","author":"Wong","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"R24-20260829","doi-asserted-by":"crossref","first-page":"23814683211061097","DOI":"10.1177\/23814683211061097","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations","volume":"7","author":"Husereau","year":"2022","journal-title":"MDM Policy Pract"},{"key":"R25-20260829","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jval.2023.04.004","article-title":"Developing criteria for health economic quality evaluation tool","volume":"26","author":"Kim","year":"2023","journal-title":"Value Health"},{"key":"R26-20260829","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1053\/j.gastro.2020.07.050","article-title":"Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: A comprehensive cost-utility analysis","volume":"159","author":"Noureddin","year":"2020","journal-title":"Gastroenterology"},{"key":"R27-20260829","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.cgh.2020.04.017","article-title":"Cost effectiveness of different strategies for detecting cirrhosis in patients with nonalcoholic fatty liver disease based on United States health care system","volume":"18","author":"Vilar-Gomez","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R28-20260829","doi-asserted-by":"crossref","first-page":"e0147237","DOI":"10.1371\/journal.pone.0147237","article-title":"Cost-effectiveness analysis: Risk stratification of nonalcoholic fatty liver disease (NAFLD) by the primary care physician using the NAFLD fibrosis score","volume":"11","author":"Tapper","year":"2016","journal-title":"PLoS One"},{"key":"R29-20260829","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/ajg.2015.241","article-title":"Cost-effective evaluation of nonalcoholic fatty liver disease with NAFLD fibrosis score and vibration controlled transient elastography","volume":"110","author":"Tapper","year":"2015","journal-title":"Official journal of the Am Coll Gastroenterol"},{"key":"R30-20260829","doi-asserted-by":"crossref","first-page":"e015659","DOI":"10.1136\/bmjopen-2016-015659","article-title":"Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: A Markov model informed by a feasibility study","volume":"7","author":"Tanajewski","year":"2017","journal-title":"BMJ Open"},{"key":"R31-20260829","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jhep.2019.05.033","article-title":"Intelligent liver function testing (iLFT): A trial of automated diagnosis and staging of liver disease in primary care","volume":"71","author":"Dillon","year":"2019","journal-title":"J Hepatol"},{"key":"R32-20260829","doi-asserted-by":"crossref","first-page":"e0251741","DOI":"10.1371\/journal.pone.0251741","article-title":"Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting","volume":"16","author":"Congly","year":"2021","journal-title":"PLoS One"},{"key":"R33-20260829","doi-asserted-by":"crossref","first-page":"e00191","DOI":"10.1097\/HC9.0000000000000191","article-title":"Cost-effectiveness analysis of noninvasive tests to identify advanced fibrosis in non-alcoholic fatty liver disease","volume":"7","author":"Gruneau","year":"2023","journal-title":"Hepatol Commun"},{"key":"R34-20260829","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jhep.2019.08.019","article-title":"Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia","volume":"71","author":"Serra-Burriel","year":"2019","journal-title":"J Hepatol"},{"key":"R35-20260829","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.3748\/wjg.v24.i30.3361","article-title":"Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis","volume":"24","author":"Leoni","year":"2018","journal-title":"World J Gastroenterol"},{"key":"R36-20260829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12876-019-1039-4","article-title":"Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease","volume":"19","author":"Srivastava","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"R37-20260829","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.2174\/1381612825666190117102111","article-title":"Diagnosis of non-alcoholic fatty liver disease (NAFLD): Current concepts","volume":"24","author":"Papatheodoridi","year":"2018","journal-title":"Curr Pharm Des"},{"key":"R38-20260829","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3390\/diagnostics14090960","article-title":"Intelligent liver function testing (iLFT): An intelligent laboratory approach to identifying chronic liver disease","volume":"14","author":"Nobes","year":"2024","journal-title":"Diagnostics"},{"key":"R39-20260829","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.2105\/AJPH.2018.304677","article-title":"The influence of industry sponsorship on the research agenda: A scoping review","volume":"108","author":"Fabbri","year":"2018","journal-title":"Am J Public Health"},{"key":"R40-20260829","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.cgh.2019.10.023","article-title":"Health care costs of patients with biopsy-confirmed nonalcoholic fatty liver disease are nearly twice those of matched controls","volume":"18","author":"Hagstr\u00f6m","year":"2020","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["International Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpvm.ijpvm_369_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:00:22Z","timestamp":1788015622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpvm.ijpvm_369_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"URL":"https:\/\/doi.org\/10.4103\/ijpvm.ijpvm_369_24","relation":{},"ISSN":["2008-7802","2008-8213"],"issn-type":[{"value":"2008-7802","type":"print"},{"value":"2008-8213","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2024-12-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}